论文部分内容阅读
[目的]探讨非小细胞肺癌(NSCLC)中巨噬细胞集落刺激因子(M-CSF)的表达及CD163+巨噬细胞浸润与患者预后的关系。[方法]收集经病理证实的NSCLC石蜡包埋组织43例。用免疫组化方法分别检测NSCLC组织中M-CSF的表达及癌巢、癌内间质、癌与正常肺交界区的CD163+巨噬细胞浸润情况,并分析其与临床病理参数、预后的关系。[结果]①M-CSF在癌组织的表达明显高于周围肺组织(0.027±0.024vs0.006±0.004,P<0.05)。②癌与正常交界区CD163+TIMs密度(67.95±42.56)高于癌内间质(57.40±34.68)、癌巢(46.28±29.41)及肿瘤周边肺(11.02±8.54),P<0.05。③肿瘤内M-CSF密度与癌巢、癌内间质及交界区CD163+TIMs密度正相关,P<0.05。④肿瘤内M-CSF高密度与肿瘤高分化相关(P<0.05),交界区CD163+TIMs密度与临床分期及淋巴结是否受累有关(P<0.05)。⑤交界区CD163+TIMs高密度患者平均生存时间(704d)明显少于低密度患者(1309d,P<0.05)。[结论]交界区CD163+巨噬细胞浸润可以作为NSCLC患者预后的独立预测指标。
[Objective] To investigate the relationship between the expression of macrophage colony-stimulating factor (M-CSF) and the infiltration of CD163 + macrophages and prognosis in non-small cell lung cancer (NSCLC). [Method] Forty-three paraffin-embedded tissues of pathologically confirmed NSCLC were collected. The expression of M-CSF and the infiltration of CD163 + macrophages in NSCLC tissues were detected by immunohistochemistry. The relationship between the expression of M-CSF and the clinicopathological parameters and prognosis was analyzed. [Results] ① The expression of M-CSF in cancer tissue was significantly higher than that in the surrounding lung tissue (0.027 ± 0.024 vs 0.006 ± 0.004, P <0.05). (2) The density of CD163 + TIMs in the borderline between cancer and normal was 67.95 ± 42.56 (57.40 ± 34.68), cancer nest (46.28 ± 29.41) and tumor surrounding lung (11.02 ± 8.54), P <0.05. (3) The density of M-CSF in the tumor was positively correlated with the density of CD163 + TIMs in cancer nests, cancer stroma and junctional area (P <0.05). (4) The high density of M-CSF in tumor correlated with tumor differentiation (P <0.05). The density of borderline CD163 + TIMs was correlated with clinical stage and lymph node involvement (P <0.05). ⑤ The average survival time of high-density CD163 + TIMs in junctional area (704d) was significantly less than that in low-density patients (1309d, P <0.05). [Conclusion] The infiltration of CD163 + macrophages in junctional area can be used as an independent predictor of prognosis in patients with NSCLC.